Comparison of prognostic significance of serum 5-S-Cysteinyldopa, LDH and S-100B protein in Stage III–IV malignant melanoma
- 1 September 2002
- journal article
- research article
- Published by Springer Nature in Pathology and Oncology Research
- Vol. 8 (3) , 183-187
Abstract
5-S-cysteinyldopa is a precursor of pheomelanin. S-100B protein is a low molecular weight, acidic, calcium binding, cytoplasmatic protein. LDH was defined as the most important serum parameter in disseminated melanoma. The aim of the present study was to compare the prognostic values of serum 5-S-Cysteinyldopa, S-100B and LDH concentrations in Stage III–IV melanoma patients. Serum samples were taken from 179 Stage III–IV melanoma patients at diagnosis. Serum 5-S-CD concentrations were determined by HPLC, S-100B protein by immunoluminometric assay while LDH by UV kinetic method. The mean/median concentrations of LDH, S-100B protein and 5-S-CD in Stage III patients ranged around the normal level. In Stage IV, the markers ranked as S100B = 5-S-CD > LDH for sensitivity, S-100B > LDH > 5-S-CD for specificity and LDH = S100B = 5-S-CD for positive predictive value, respectively. Furthermore, mean marker concentrations of patients with progressive disease differed significantly from nonprogresssive cases (when staging categories have been disregarded). Survival analysis indicated, that the initially elevated LDH and S-100B level in Stage IV disease predicts comparably short survival. Results of our study suggest that these serum marker values correlate well with Stages and disease progression. In Stage IV melanoma, the markers had appropriate sensitivity, high specificity as well as important positive predictive value. Among the studied serum markers S-100B protein and LDH proved to be similarly reliable in respect to the clinical outcome.Keywords
This publication has 29 references indexed in Scilit:
- S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase.2001
- Are responses to therapy of metastasized malignant melanoma reflected by decreasing serum values of S100β or melanoma inhibitory activity (MIA)?Melanoma Research, 2001
- S100 protein serum levels in cutaneous malignant melanoma.Oncology Reports, 1998
- Clinical and prognostic relevance of serum S‐100β protein in malignant melanomaBritish Journal of Dermatology, 1998
- Urinary excretion of 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid in childrenActa Dermato-Venereologica, 1998
- Modulation of 5-S-cysteinyldopa formation by tyrosinase activity and intracellular thiols in human melanoma cellsMelanoma Research, 1996
- Clinical significance of serum S100 in metastatic malignant melanomaEuropean Journal of Cancer, 1995
- Seasonal Variation in Serum Concentration of 5‐S‐Cysteinyldopa and 6‐Hydroxy‐5‐Methoxyindole‐2‐Carboxylic Acid in Healthy JapanesePigment Cell Research, 1995
- Neuron-specific enolase as a prognostic factor in metastatic malignant melanomaEuropean Journal of Cancer, 1992
- The quantitative determination of 5-s-cysteinyldopa and dopa in normal serum and in serum from patients with malignant melanoma by means of high-pressure liquid chromatographyClinica Chimica Acta, 1978